These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 861376)

  • 21. The relationship between humoral stimulating activity and colony stimulating factor.
    Karp JE; Shadduck RK; Burke PJ; Shaper JH
    Exp Hematol; 1983 Aug; 11(7):639-48. PubMed ID: 6603985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasmablastic IgM multiple myeloma with hypocellular bone marrow.
    Arter ZL; Miles D; Mignano S; Cordaro D; Roswarski J
    Ann Hematol; 2020 Apr; 99(4):895-896. PubMed ID: 32055929
    [No Abstract]   [Full Text] [Related]  

  • 23. DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.
    Hewett DR; Vandyke K; Lawrence DM; Friend N; Noll JE; Geoghegan JM; Croucher PI; Zannettino ACW
    Neoplasia; 2017 Dec; 19(12):972-981. PubMed ID: 29091798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
    Pasqualetti P; Colantonio D; Casale R
    Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of residual murine LPC-1 myeloma cells from bone marrow cell mixture after purging by 4-hydroperoxycyclophosphamide.
    Frondoza CG; Sinha S; Trivedi SM; Humphrey RL; Colvin OM
    Exp Hematol; 1987 Jul; 15(6):715-8. PubMed ID: 3297761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
    Caligaris-Cappio F; Bergui L; Tesio L; Pizzolo G; Malavasi F; Chilosi M; Campana D; van Camp B; Janossy G
    J Clin Invest; 1985 Sep; 76(3):1243-51. PubMed ID: 2931452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.
    Rawstron AC; Davies FE; DasGupta R; Ashcroft AJ; Patmore R; Drayson MT; Owen RG; Jack AS; Child JA; Morgan GJ
    Blood; 2002 Nov; 100(9):3095-100. PubMed ID: 12384404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio.
    Riccardi A; Montecucco C; Danova M; Ucci G; Merlini G; Ascari E
    Cancer Treat Rep; 1985 Sep; 69(9):971-5. PubMed ID: 4028038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
    Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
    [No Abstract]   [Full Text] [Related]  

  • 30. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
    Klein B; Seckinger A; Moehler T; Hose D
    Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy.
    Boccadoro M; Gavarotti P; Fossati G; Pileri A; Marmont F; Neretto G; Gallamini A; Volta C; Tribalto M; Testa MG
    Br J Haematol; 1984 Dec; 58(4):689-96. PubMed ID: 6518137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor.
    Gazitt Y; Tian E; Barlogie B; Reading CL; Vesole DH; Jagannath S; Schnell J; Hoffman R; Tricot G
    Blood; 1996 Jan; 87(2):805-11. PubMed ID: 8555506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early plasma cell recruitment in multiple myeloma following chemotherapy.
    Ucci G; Riccardi A; Dörmer P; Danova M; Luoni R
    Cell Tissue Kinet; 1988 Nov; 21(6):405-9. PubMed ID: 3251633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of cell proliferation in normal and pathological bone marrow biopsies: a study using double sequential immunophenotyping on paraffin sections.
    Pellegrini W; Facchetti F; Marocolo D; Salvi L; Capucci A; Tironi A; Rossi G
    Histopathology; 1995 Nov; 27(5):397-405. PubMed ID: 8575729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colony growth and self renewal of plasma cell precursors in multiple myeloma.
    Takahashi T; Lim B; Jamal N; Tritchler D; Lockwood G; McKinney S; Bergsagel DE; Messner HA
    J Clin Oncol; 1985 Dec; 3(12):1613-23. PubMed ID: 4067612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Kinetic studies on human myeloma cells following melphalan administration].
    Hara H; Nakai K; Nagai K
    Nihon Ketsueki Gakkai Zasshi; 1971 Oct; 34(5):614-21. PubMed ID: 5170343
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma.
    Terpstra WE; Lokhorst HM; Blomjous F; Meuwissen OJ; Dekker AW
    Br J Haematol; 1992 Sep; 82(1):46-9. PubMed ID: 1419801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
    Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
    PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.
    Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A
    Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth kinetics of plasma cell myeloma.
    Drewinko B; Alexanian R
    J Natl Cancer Inst; 1977 May; 58(5):1247-53. PubMed ID: 857025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.